Inhibition Of PI3K/mTOR Overcomes Nilotinib Resistance In BCR-ABL1 Positive Leukemia Cells

被引：0
|
作者：
Ding, Jie
Romani, Julia
Zaborski, Margarete
MacLeod, Roderick A. F.
Nagel, Stefan
Drexler, Hans G.
Quentmeier, Hilmar
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.4906.4906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4906
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Dynamics of BCR-ABL1 transcripts during nilotinib therapy in patients with chronic myeloid leukemia (CML)
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Jones, Dan
    O'Brien, Susan
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 870A - 870A
  • [22] Pharmacological IRS1/2 Inhibition Reduces Cell Viability in BCR-ABL1 Positive Cells
    Scopim-Ribeiro, Renata
    Machado-Neto, Joao Agostinho
    Campos, Paula de Melo
    Santos Duarte, Adriana da Silva
    Scheucher, Priscila Santos
    Goes, Amelia
    Olalla Saad, Sara Teresinha
    Simoes, Belinda Pinto
    Rego, Eduardo Magalhaes
    Traina, Fabiola
    BLOOD, 2015, 126 (23)
  • [23] Stroma-driven resistance to PI3K/mTOR inhibition.
    Muranen, Taru
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 16 - 16
  • [24] Apicidin overcomes TRAIL-resistance on Bcr-AbI expressing K562 cells through inhibition of PI3K/AKT mediated pathway
    Park, S. J.
    Kim, M. J.
    Song, H. S.
    Kim, H. B.
    Kang, C. D.
    Kim, S. H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 71 - 71
  • [25] MUTAGENESIS OF BCR-ABL1 IS REQUIRED FOR RESISTANCE DEVELOPMENT IN DE NOVO CHRONIC MYELOID LEUKEMIA KCL-22 CELLS BUT NOT IN RELAPSED KCL-22 CELLS EXPRESSING BCR-ABL1 INDEPENDENT RESISTANCE
    Curik, N.
    Polivkova, V.
    Kalina, T.
    Kanderova, V.
    Linhartova, J.
    Savvulidi, F.
    Toman, O.
    Srutova, K.
    Ransdorfova, S.
    Brezinova, J.
    Klamova, H.
    Polakova, K. Machova
    HAEMATOLOGICA, 2017, 102 : 428 - 428
  • [26] Inhibition of the PI3K/AKT/mTOR Pathway Leads to Down-Regulation of c-Myc and Overcomes Resistance to ATRA in Acute Myeloid Leukemia
    Swords, Ronan T.
    Schenk, Tino
    Stengel, Sven
    Sylvina, Veronica
    Petrie, Kevin R.
    Perez, Aymee
    Ana, Rodriguez
    Watts, Justin M.
    Vargas, Fernando
    Elias, Roy
    Zelent, Arthur
    BLOOD, 2015, 126 (23)
  • [27] A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia
    Lim, Ye Seul
    Jeong, Na-Rae
    Yoo, Sun-Mi
    Kim, Han Wool
    Lee, Song Hee
    Kim, Dong-Wook
    BLOOD, 2023, 142
  • [28] Inhibition of PI3K/mTOR leads to adaptive resistance in extracellular matrix attached cancer cells
    Muranen, Taru E.
    Selfors, Laura
    Worster, Devin
    Iwanicki, Marcin
    Song, Loling
    Moriaes, Fabiana
    Mills, Gordon B.
    Brugge, Joan S.
    CANCER RESEARCH, 2012, 72
  • [29] Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
    Muranen, Taru
    Selfors, Laura M.
    Worster, Devin T.
    Iwanicki, Marcin P.
    Song, Loling
    Morales, Fabiana C.
    Gao, Sizhen
    Mills, Gordon B.
    Brugge, Joan S.
    CANCER CELL, 2012, 21 (02) : 227 - 239
  • [30] Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells
    Muranen, T.
    Selfors, L.
    Iwanicki, M.
    Mills, G. B.
    Brugge, J. S.
    MOLECULAR BIOLOGY OF THE CELL, 2012, 23
12345